Target: NDR1 (pSer281+pThr282)
Conjugate: FITC
Product Type: Polyclonal
Immunogen: A phospho-specific peptide corresponding to residues surrounding Ser281 and Thr282 of human NDR1 (AA278-285)
Swiss-Prot: Q15208
Purification: Peptide Affinity Purified
Storage Buffer: PBS pH7.4, 50% glycerol, 0.025% Thimerosal *Storage buffer may change when conjugated
Specificity: Detects 54.19 kDa.
Cellular Localization: Nucleus,Cytoplasm
Tissue Specificity: Ubiquitously expressed with highest levels observed in peripheral blood leukocytes.
Scientific Background: STK38 is a negative regulator of MAP3K1/2 signalling. Converts MAP3K2 from its phosphorylated form to its nonphosphorylated form and inhibits autophosphorylation of MAP3K2. The MAPK/ERK pathway has been implicated in oncogenesis as either a promoter or inhibitor depending on the cancer system. Thus, the role of STK38 in cancer is likely highly contextual.
Field of Use: Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.
English
Deutsch
